Matched-pair, 86Y/90Y-labeled, bivalent RGD/bombesin antagonist, [RGD-Glu-[DO3A]-6-Ahx-RM2], as a potential theranostic agent for prostate cancer

Add time:08/01/2019    Source:sciencedirect.com

IntroductionIn this study, we describe development of a true matched-pair theranostic agent that is able to target the αVβ3 integrin and the gastrin releasing peptide receptor (GRPR). We herein describe methods to metallate and characterize the new conjugate and to validate its biological efficacy by in vitro and in vivo methods.

We also recommend Trading Suppliers and Manufacturers of PHE-LEU-GLU-GLU-VAL AMMONIUM (cas 104180-33-8). Pls Click Website Link as below: cas 104180-33-8 suppliers

Prev:Ammonium mediated changes in carbon and nitrogen metabolisms induce resistance against Pseudomonas syringae in tomato plants
Next:Measurement of the agonistic activities of monohydroxylated polychlorinated biphenyls at the retinoid X and retinoic acid receptors using recombinant yeast cells)